Image

Global Spinal Muscular Atrophy (SMA) Treatment Market - Industry Trends and Forecast to 2028

  • Pharmaceutical
  • Upcoming Report
  • Nov 2021
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60
  • Pharmaceutical
  • Upcoming Report
  • Nov 2021
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Spinal Muscular Atrophy (SMA) Treatment Market, By Drugs (Nusinersen, Onasemnogene Abeparvovec and Others), Types (Werdnig-Hoffmann Disease, Infant SMA, Kugelberg-Welander Disease and Adult SMA), Treatment (Medication, Physical Therapy, Surgery, Others), Route of Administration (Intrathecal, Intraspinal, Subcutaneous and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Online Pharmacy), End-Users (Hospitals, Homecare, Specialty Clinics and Others), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2028.

Spinal Muscular Atrophy (SMA) Treatment Market Market Analysis and Insights : Global Spinal Muscular Atrophy (SMA) Treatment Market

The spinal muscular atrophy (SMA) treatment market is expected to witness market growth at a rate of 14.1% in the forecast period of 2021 to 2028. Data Bridge Market Research report on spinal muscular atrophy (SMA) treatment market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecast period while providing their impacts on the market’s growth. The rise in the prevalence of heart disorder globally is escalating the growth of spinal muscular atrophy (SMA) treatment market.

Spinal muscular atrophy (SMA) refers to an autosomal recessive neurodegenerative genetic disorder that is generally characterized by weakening of muscles and atrophy. The condition occurs because of the mutation in the survival motor neuron. Patients with spinal muscular atrophy possess issues in standing, walking and controlling their head movements.

The increase in the number of people suffering from spinal muscular atrophy (SMA) across the globe acts as one of the major factors driving the growth of spinal muscular atrophy (SMA) treatment market. The increase in number of initiatives to improve treatment options for rare diseases and surge in demand for drugs for the treatment including Nusinersen, Onasemnogene Abeparvovec and Others accelerate the market growth. The rise in the number of research and development activities for improving the therapies and initiatives undertaken by various public, as well as nonprofit, organizations for creating awareness regarding SMA further influence the market. Additionally, surge in healthcare expenditure, development in technology, increase in investments, growth in awareness and various drug designation to novel drugs positively affect the spinal muscular atrophy (SMA) treatment market. Furthermore, advancements in the drugs extend profitable opportunities to the market players in the forecast period of 2021 to 2028.

On the other hand, high cost associated with the treatment and diagnosis are expected to obstruct the market growth. Lack of skilled expertise is projected to challenge the spinal muscular atrophy (SMA) treatment market in the forecast period of 2021-2028.

This spinal muscular atrophy (SMA) treatment market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info spinal muscular atrophy (SMA) treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth. 

Global Spinal Muscular Atrophy (SMA) Treatment Market Scope and Market Size

The spinal muscular atrophy (SMA) treatment market is segmented on the basis of drugs, type, treatment, route of administration, distribution channel and end user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of drugs, the spinal muscular atrophy (SMA) treatment market is segmented into nusinersen, onasemnogene abeparvovec and others.
  • On the basis of type, the spinal muscular atrophy (SMA) treatment market is segmented into Werdnig-Hoffmann disease, infant SMA, Kugelberg-Welander disease and adult SMA.
  • On the basis of treatment, the spinal muscular atrophy (SMA) treatment market is segmented into medication, physical therapy, surgery and others.
  • On the basis of route of administration, the spinal muscular atrophy (SMA) treatment market is segmented into intrathecal, intraspinal, subcutaneous and others.
  • On the basis of distribution channel, the spinal muscular atrophy (SMA) treatment market is segmented as hospital pharmacy, online pharmacy, and retail pharmacy.
  • On the basis of end user, the spinal muscular atrophy (SMA) treatment market is segmented into hospitals, homecare, specialty clinics and others

Spinal Muscular Atrophy (SMA) Treatment Market Country Level Analysis

The spinal muscular atrophy (SMA) treatment market is analyzed and market size information is provided by country, drugs, type, treatment, route of administration, distribution channel and end user as referenced above.

The countries covered in the global spinal muscular atrophy (SMA) treatment market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

North America dominates the spinal muscular atrophy (SMA) treatment market due to the presence of advanced healthcare system within the region. Asia-Pacific is expected to witness high growth during the forecast period of 2021 to 2028 because of the large patient population in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

The spinal muscular atrophy (SMA) treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Spinal Muscular Atrophy (SMA) Treatment Market Share Analysis

The spinal muscular atrophy (SMA) treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related spinal muscular atrophy (SMA) treatment market.

The major players covered in the spinal muscular atrophy (SMA) treatment market report are Novartis AG, F. Hoffmann-La Roche Ltd, Biogen, Boehringer Ingelheim International GmbH, Pfizer Inc., Ionis Pharmaceuticals, Inc., CYTOKINETICS, INC., Regeneron Pharmaceuticals, Inc., Abbott, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, AstraZeneca, Salarius Pharmaceuticals, Inc., Scholar Rock, Leadiant Biosciences, Inc., Catalyst Pharma, PTC Therapeutics, Natera, Inc., and UCB Pharma Ltd, among other domestic and global players. Market share data is available for global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.


SKU-
Why Choose Us


Frequently Asked Questions